Table 2.

Modified Rankin Scale Score at 90 Days and Secondary Outcomes

	EVT alone group (n = 116)	Bridging therapy group (n = 118)	Unadjusted difference (95% CI)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
Primary efficacy outcome
Functional independence	60 (51.7)	56 (47.5)	4.3 (−8.4–ꝏ)	1.19 (0.71–1.98)	1.21 (0.68–2.15)
Secondary efficacy outcome
Excellent outcome	45 (38.8)	46 (39.0)	0.2 (−12.1–12.5)	0.99 (0.59–1.68)	0.96 (0.53–1.74)
Disability level, median (IQR), mRS score	2 (1–6)	3 (1–6)	0 (0–0)	0.96 (0.61–1.51)	0.96 (0.60–1.54)
EQ-5D-5L score, median (IQR)	0.81 (0.00–1.00)	0.73 (0.00–1.00)	0 (0–0.005)	0.01 (−0.11–0.13)	0.004 (−0.01–0.11)

Abbreviations: mRS Modified Rankin Scale Score, EQ-5D-5L European Quality of Life 5-Dimensions 5-Level questionnaire, IQR Interquartile range, EVT Endovascular treatment, IVT Intravenous thrombolysis, OR Odds ratio, CI Confidence interval